Fulgent Genetics Inc. has announced preliminary clinical data from its ongoing phase 2 trial investigating FID-007 in combination with cetuximab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data, with a cutoff date of September 25, 2025, will be presented at the European Society for Medical Oncology (ESMO) conference in Berlin, Germany, on October 20, 2025. In the study, 39 patients were randomized and 36 received at least one dose of treatment. FID-007 combined with cetuximab showed an objective response rate of 44% in the 75 mg/m2 arm and 59% in the 125 mg/m2 arm, with an overall response rate of 51%. Median progression-free survival was 9.2 months for the lower dose and 7.8 months for the higher dose, compared to a historical standard-of-care median of 2.3 months. The combination treatment exhibited a favorable safety and tolerability profile, with a 6% rate of treatment-related serious adverse events. The optimal dose of FID-007 will be determined after further data maturation.